- In April 2024, Aspen Pharmacare (South Africa), a major player in the anticoagulant market, announced the expansion of its production capabilities for injectable anticoagulants at its Gqeberha facility. This strategic move aims to meet the growing domestic and regional demand for heparin-based therapies, reinforcing Aspen’s position in the South African pharmaceutical manufacturing sector and improving supply security across Southern Africa
- In March 2024, Cipla Medpro (South Africa) launched a cost-effective generic version of rivaroxaban, a Non-VKA Oral Anticoagulant (NOAC), to improve accessibility for patients at risk of stroke and venous thromboembolism. The launch supports national healthcare goals by expanding access to life-saving anticoagulation therapy through both public and private healthcare channels
- In February 2024, Adcock Ingram partnered with South African hospital networks to roll out a pilot program focused on improving anticoagulant adherence in patients recovering from joint replacement surgery. The initiative utilizes digital monitoring tools and follow-up care coordination to reduce post-operative complications such as deep vein thrombosis (DVT), highlighting a shift toward value-based care in the South African context
- In January 2024, Bayer AG (South Africa) initiated a nationwide awareness campaign in collaboration with cardiologists and primary care providers to improve early diagnosis and treatment of atrial fibrillation (AF). The campaign promotes the use of modern NOACs over traditional warfarin due to better safety profiles and fewer dietary restrictions, aiming to reduce the incidence of stroke across high-risk populations
- In December 2023, Fresenius Kabi South Africa received regulatory approval for a new low-molecular-weight heparin (LMWH) formulation optimized for subcutaneous delivery. This innovation is expected to support hospital and ambulatory settings with enhanced patient compliance and streamlined dosing protocols, strengthening Fresenius Kabi’s product portfolio in the anticoagulant segment
